Amivantamab is a targeted bispecific antibody and works by targeting cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumors grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack
August 24, 2026 at 5:26 PM
Amivantamab is a targeted bispecific antibody and works by targeting cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumors grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack
In a new #ScienceSignaling study, researchers introduce extracellular #TurboID, a refinement of the popular proteomics tool that interrogates #ProteinProteinInteractions on the exterior cell membrane, and characterize interactions between #EGFR and #LDLR. scim.ag/3DgfJr9
Extracellular proximal interaction profiling by cell surface–targeted TurboID reveals LDLR as a partner of liganded EGFR
A modified form of TurboID identifies extracellular interactions between transmembrane proteins.
www.science.org
December 13, 2024 at 5:22 PM
In a new #ScienceSignaling study, researchers introduce extracellular #TurboID, a refinement of the popular proteomics tool that interrogates #ProteinProteinInteractions on the exterior cell membrane, and characterize interactions between #EGFR and #LDLR. scim.ag/3DgfJr9
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
www.nature.com/articles/s41...
www.nature.com/articles/s41...
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer - Signal Transduction and Targeted Therapy
Signal Transduction and Targeted Therapy - CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
www.nature.com
December 6, 2024 at 4:38 AM
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
www.nature.com/articles/s41...
www.nature.com/articles/s41...
ASCO has released an updated Rapid Recommendation for stage III NSCLC in JCO Oncology Practice. Update now includes targeted therapy: consolidation osimertinib after chemoradiation for #EGFR NSCLC, adjuvant osimertinib or alectinib for resected EGFR or ALK NSCLC. #LCSM
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights | JCO Oncology Practice
ascopubs.org
November 19, 2024 at 2:20 AM
ASCO has released an updated Rapid Recommendation for stage III NSCLC in JCO Oncology Practice. Update now includes targeted therapy: consolidation osimertinib after chemoradiation for #EGFR NSCLC, adjuvant osimertinib or alectinib for resected EGFR or ALK NSCLC. #LCSM
ascopubs.org/doi/10.1200/...
ascopubs.org/doi/10.1200/...
Glad to share our work in Science Advances on how targeted cancer therapy promotes the persistence of topoisomerase 1 cleavage complexes, which are involved in the emergence of resistance in lung cancer. Many thanks to Olivier Sordet's lab and to all co-authors. www.science.org/doi/10.1126/...
Persistent TOP1 cleavage complexes in drug-tolerant cells drive adaptive resistance to EGFR-targeted therapies in lung cancer
Resistance to targeted cancer therapies often arises from drug-tolerant cells, which survive treatment by entering a nonproliferative state. Over time, these cells can acquire mutations that contribut...
www.science.org
September 29, 2026 at 9:52 AM
Glad to share our work in Science Advances on how targeted cancer therapy promotes the persistence of topoisomerase 1 cleavage complexes, which are involved in the emergence of resistance in lung cancer. Many thanks to Olivier Sordet's lab and to all co-authors. www.science.org/doi/10.1126/...
🧬 CRISPR Treatment Shrinks Tumours
Scientists used CRISPR gene editing to remove a key gene from head & neck cancer cells, eliminating tumours in 50% of treated mice.
🔗 doi.org/10.1002/advs...
#SciComm 🧪 #Cancer #CRISPR
Scientists used CRISPR gene editing to remove a key gene from head & neck cancer cells, eliminating tumours in 50% of treated mice.
🔗 doi.org/10.1002/advs...
#SciComm 🧪 #Cancer #CRISPR
Targeted CRISPR/Cas9 Lipid Nanoparticles Elicits Therapeutic Genome Editing in Head and Neck Cancer
αEGFR-t-SOX2-cLNPs achieved specific delivery to tumor cells, resulting in 90% tumor growth inhibition of HNSCC-bearing mice. This response is sustained for 12 weeks, with 50% of the mice showing tum....
doi.org
March 13, 2025 at 9:18 PM
🧬 CRISPR Treatment Shrinks Tumours
Scientists used CRISPR gene editing to remove a key gene from head & neck cancer cells, eliminating tumours in 50% of treated mice.
🔗 doi.org/10.1002/advs...
#SciComm 🧪 #Cancer #CRISPR
Scientists used CRISPR gene editing to remove a key gene from head & neck cancer cells, eliminating tumours in 50% of treated mice.
🔗 doi.org/10.1002/advs...
#SciComm 🧪 #Cancer #CRISPR
Somewhere between 10 and 20% of patients have EGFR+ lung cancer. It’s more common in women and people of Asian descent. It occurs often in a different part of the lung than a smoking-related cancer (mine was in my upper left lung). Thankfully, there are targeted genetic drugs, like the one I take.
January 16, 2026 at 2:12 AM
Somewhere between 10 and 20% of patients have EGFR+ lung cancer. It’s more common in women and people of Asian descent. It occurs often in a different part of the lung than a smoking-related cancer (mine was in my upper left lung). Thankfully, there are targeted genetic drugs, like the one I take.
☕Yu et al. identify HELDR as a #lncRNA co-amplified with EGFR in #glioblastoma to promote a KAT7-activated malignancy program, which can be potentially targeted with anti-EGFR therapy for improved therapeutic outcomes.
👉https://rdcu.be/fdBOX
bit.ly/4tnYyZN
👉https://rdcu.be/fdBOX
bit.ly/4tnYyZN
An EGFR co-amplified lncRNA HELDR promotes glioblastoma malignancy through KAT7-driven gene programs - Nature Cell Biology
Yu et al. identify HELDR as a lncRNA co-amplified with EGFR in glioblastoma to promote a KAT7-activated malignancy programme, which can be potentially targeted with anti-EGFR therapy for improved ther...
bit.ly
April 15, 2026 at 2:58 PM
☕Yu et al. identify HELDR as a #lncRNA co-amplified with EGFR in #glioblastoma to promote a KAT7-activated malignancy program, which can be potentially targeted with anti-EGFR therapy for improved therapeutic outcomes.
👉https://rdcu.be/fdBOX
bit.ly/4tnYyZN
👉https://rdcu.be/fdBOX
bit.ly/4tnYyZN
Advances in research have brought us targeted therapies for lung cancers like EGFR, ALK & RET. These are often more tolerable & allow good quality of life. Like for Melanie wh EGFR LC in England. She's not only leading a normal life, but hopeful for others. #LCAM @oncogenecancer.bsky.social
November 21, 2024 at 5:48 PM
Advances in research have brought us targeted therapies for lung cancers like EGFR, ALK & RET. These are often more tolerable & allow good quality of life. Like for Melanie wh EGFR LC in England. She's not only leading a normal life, but hopeful for others. #LCAM @oncogenecancer.bsky.social
New research shows #EGFR TKIs, used in EGFR+ #lungcancer, may also help those with rare BRAF class 3 mutations in NSCLC. Two patients responded to erlotinib after standard treatments failed, offering hope for new targeted therapy options. Read more: ascopubs.org/doi/10.1200/... #LCSM
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations | JCO Precision Oncology
PURPOSEPatients with tumors harboring BRAF class 3 mutations lack targeted therapies. These mutations are characterized by low/absent
BRAF kinase domain activation and are believed to amplify already ...
ascopubs.org
December 15, 2024 at 9:00 AM
New research shows #EGFR TKIs, used in EGFR+ #lungcancer, may also help those with rare BRAF class 3 mutations in NSCLC. Two patients responded to erlotinib after standard treatments failed, offering hope for new targeted therapy options. Read more: ascopubs.org/doi/10.1200/... #LCSM
New paper out today in J. Med. Chem. pubs.acs.org/doi/10.1021/...
Profiling and Optimizing Targeted Covalent Inhibitors through EGFR-Guided Studies
Targeted covalent inhibitors (TCIs) are actively pursued in drug discovery due to their prolonged target engagement and clinical efficacy. Although kinetic parameters provide a path to their optimizat...
pubs.acs.org
August 13, 2025 at 6:19 PM
New paper out today in J. Med. Chem. pubs.acs.org/doi/10.1021/...
Spatial dynamics of the tumor microenvironment in emerging resistance to targeted therapy in EGFR-mutated NSCLC https://www.biorxiv.org/content/10.1101/2025.02.10.637543v1
February 13, 2025 at 6:49 PM
Spatial dynamics of the tumor microenvironment in emerging resistance to targeted therapy in EGFR-mutated NSCLC https://www.biorxiv.org/content/10.1101/2025.02.10.637543v1
What happens if an early stage #lungcancer comes back?
For Mel, now living with stage 4 EGFR lung cancer, it meant going onto a life-saving targeted therapy.
Here she and her partner Sarah explain the wonders of research & why we need more.
#LCAM @younglungcancer.bsky.social
For Mel, now living with stage 4 EGFR lung cancer, it meant going onto a life-saving targeted therapy.
Here she and her partner Sarah explain the wonders of research & why we need more.
#LCAM @younglungcancer.bsky.social
November 22, 2024 at 1:19 PM
What happens if an early stage #lungcancer comes back?
For Mel, now living with stage 4 EGFR lung cancer, it meant going onto a life-saving targeted therapy.
Here she and her partner Sarah explain the wonders of research & why we need more.
#LCAM @younglungcancer.bsky.social
For Mel, now living with stage 4 EGFR lung cancer, it meant going onto a life-saving targeted therapy.
Here she and her partner Sarah explain the wonders of research & why we need more.
#LCAM @younglungcancer.bsky.social
Long-term single-molecule tracking reveals EGFR, HER2, and HER3 dimerization dynamics. Oncogenic mutations stabilize dimerization, impacting signaling. Insights offer new paths for targeted therapies. PMID:42054992, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5 #Medsky 🧪
https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5
No description available
www.cell.com
July 19, 2026 at 10:00 AM
Long-term single-molecule tracking reveals EGFR, HER2, and HER3 dimerization dynamics. Oncogenic mutations stabilize dimerization, impacting signaling. Insights offer new paths for targeted therapies. PMID:42054992, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5 #Medsky 🧪
Iza-Bren (EGFR×HER3 ADC): A Next-Generation Dual-Targeted Antibody–Drug Conjugate
oncodaily.com/drugs/iza-br...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #ADC
oncodaily.com/drugs/iza-br...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #ADC
Iza-Bren (EGFR×HER3 ADC): A Next-Generation Dual-Targeted Antibody–Drug Conjugate - OncoDaily
Iza-Bren is an EGFR×HER3 bispecific ADC showing significant clinical activity and regulatory momentum in EGFR-driven solid tumors.
oncodaily.com
January 12, 2026 at 1:05 AM
Iza-Bren (EGFR×HER3 ADC): A Next-Generation Dual-Targeted Antibody–Drug Conjugate
oncodaily.com/drugs/iza-br...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #ADC
oncodaily.com/drugs/iza-br...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #ADC
🧬Can one kinase be targeted at two sites?
A study introduces bitopic inhibition using BCR::ABL1 as a model. PonatiLink-2 links ponatinib and asciminib to target the ATP and allosteric sites, improving activity against resistant mutants and kinase selectivity. The strategy was also extended to EGFR.
A study introduces bitopic inhibition using BCR::ABL1 as a model. PonatiLink-2 links ponatinib and asciminib to target the ATP and allosteric sites, improving activity against resistant mutants and kinase selectivity. The strategy was also extended to EGFR.
September 30, 2026 at 1:00 PM
🧬Can one kinase be targeted at two sites?
A study introduces bitopic inhibition using BCR::ABL1 as a model. PonatiLink-2 links ponatinib and asciminib to target the ATP and allosteric sites, improving activity against resistant mutants and kinase selectivity. The strategy was also extended to EGFR.
A study introduces bitopic inhibition using BCR::ABL1 as a model. PonatiLink-2 links ponatinib and asciminib to target the ATP and allosteric sites, improving activity against resistant mutants and kinase selectivity. The strategy was also extended to EGFR.
Did you know that some cancer treatments cause cardiotoxicity?
These include some chemo, radiotherapy, immuno & targeted therapies (including some ALK, EGFR & HER2 inhibitors).
The 🔑 is learning more & integrating cardio oncology into your care team👇
www.oncogeneresearch.org/cardiotoxicity
#lcsm
These include some chemo, radiotherapy, immuno & targeted therapies (including some ALK, EGFR & HER2 inhibitors).
The 🔑 is learning more & integrating cardio oncology into your care team👇
www.oncogeneresearch.org/cardiotoxicity
#lcsm
February 8, 2025 at 3:50 PM
Did you know that some cancer treatments cause cardiotoxicity?
These include some chemo, radiotherapy, immuno & targeted therapies (including some ALK, EGFR & HER2 inhibitors).
The 🔑 is learning more & integrating cardio oncology into your care team👇
www.oncogeneresearch.org/cardiotoxicity
#lcsm
These include some chemo, radiotherapy, immuno & targeted therapies (including some ALK, EGFR & HER2 inhibitors).
The 🔑 is learning more & integrating cardio oncology into your care team👇
www.oncogeneresearch.org/cardiotoxicity
#lcsm
The study showed for patients with my particular mutation, EGFR 19 Deletion, who've had surgery or radiation, there's a 42% lower risk of my cancer progressing than if I was just taking my one-pill-a-day targeted therapy. I like that number :)
October 18, 2025 at 1:59 PM
The study showed for patients with my particular mutation, EGFR 19 Deletion, who've had surgery or radiation, there's a 42% lower risk of my cancer progressing than if I was just taking my one-pill-a-day targeted therapy. I like that number :)
While catching up with literature, here's a bispecific paper "Structure-Based Design of New LSD1/EGFRL858R/T790M Dual Inhibitors for Treating EGFR Mutant NSCLC Cancers" pubs.acs.org/doi/10.1021/... Is there a review on target relationships for bispecifics - e.g paralog targeted, unrelated etc?
Structure-Based Design of New LSD1/EGFRL858R/T790M Dual Inhibitors for Treating EGFR Mutant NSCLC Cancers
Epigenetic changes, such as LSD1 dysregulation, contribute to acquired resistance in EGFR mutant NSCLCs and reduce the effectiveness of current therapeutics. To address the challenges, we herein repor...
pubs.acs.org
March 3, 2025 at 2:06 PM
While catching up with literature, here's a bispecific paper "Structure-Based Design of New LSD1/EGFRL858R/T790M Dual Inhibitors for Treating EGFR Mutant NSCLC Cancers" pubs.acs.org/doi/10.1021/... Is there a review on target relationships for bispecifics - e.g paralog targeted, unrelated etc?
From the discovery of #EGF and #EGFR to today’s targeted therapies, this @royalsociety.org review from Drs. Katerina Politi, Roy Herbst, and Meina Wang looks at this milestone in precision oncology.
royalsocietypublishing.org/rstb/article...
@yalepathology.bsky.social
royalsocietypublishing.org/rstb/article...
@yalepathology.bsky.social
Looking back on the history of epidermal growth factor receptor mutations in lung cancer
Abstract. The discovery of the epidermal growth factor receptor (EGFR) represents a landmark achievement in biomedical science, laying the foundation for o
royalsocietypublishing.org
August 27, 2026 at 5:23 PM
From the discovery of #EGF and #EGFR to today’s targeted therapies, this @royalsociety.org review from Drs. Katerina Politi, Roy Herbst, and Meina Wang looks at this milestone in precision oncology.
royalsocietypublishing.org/rstb/article...
@yalepathology.bsky.social
royalsocietypublishing.org/rstb/article...
@yalepathology.bsky.social
Great news: @astrazeneca.bsky.social’s Tagrisso (osimertinib) becomes 1st inhibitor approved for EGFR #lungcancer (ex 19 & 21) in the EU.
“New standard of care to patients who have historically experienced early progression after chemoradiation therapy.”
www.astrazeneca.com/media-centre...
#LCSM
“New standard of care to patients who have historically experienced early progression after chemoradiation therapy.”
www.astrazeneca.com/media-centre...
#LCSM
December 23, 2024 at 9:39 AM
Great news: @astrazeneca.bsky.social’s Tagrisso (osimertinib) becomes 1st inhibitor approved for EGFR #lungcancer (ex 19 & 21) in the EU.
“New standard of care to patients who have historically experienced early progression after chemoradiation therapy.”
www.astrazeneca.com/media-centre...
#LCSM
“New standard of care to patients who have historically experienced early progression after chemoradiation therapy.”
www.astrazeneca.com/media-centre...
#LCSM
People with relapsed small cell #lungcancer need more treatment options.
🆕 early study of targeted ADC izalontamab brengitecan reports encouraging results. Treatment is designed to target EGFR & HER3, with HER3 also emerging as a potential biomarker for response.
ascopubs.org/doi/full/10.... #LCSM
🆕 early study of targeted ADC izalontamab brengitecan reports encouraging results. Treatment is designed to target EGFR & HER3, with HER3 also emerging as a potential biomarker for response.
ascopubs.org/doi/full/10.... #LCSM
July 26, 2026 at 9:40 PM
People with relapsed small cell #lungcancer need more treatment options.
🆕 early study of targeted ADC izalontamab brengitecan reports encouraging results. Treatment is designed to target EGFR & HER3, with HER3 also emerging as a potential biomarker for response.
ascopubs.org/doi/full/10.... #LCSM
🆕 early study of targeted ADC izalontamab brengitecan reports encouraging results. Treatment is designed to target EGFR & HER3, with HER3 also emerging as a potential biomarker for response.
ascopubs.org/doi/full/10.... #LCSM
This paper is a beautiful example of what a large direct-to-consumer cohort makes possible: T790M is rare enough that its risk had never been reliably estimated. Its origins and distribution may support geographically targeted testing.
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
Germline EGFR T790M mutation and lung cancer risk
Most lung cancers are tobacco related, with genetic factors influencing smoking behavior identified through genome-wide association studies. However, inherited risk in familial and non-smoking-related...
www.science.org
September 17, 2026 at 11:09 PM
This paper is a beautiful example of what a large direct-to-consumer cohort makes possible: T790M is rare enough that its risk had never been reliably estimated. Its origins and distribution may support geographically targeted testing.
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
📍 The combo of panitumumab (anti-EGFR antibody) + carboplatin/paclitaxel achieved a 30.2% pCR/RCB-I rate, a 6x improvement over historical controls (5%) 💊
📍 Key Highlights
✅ Targeted EGFR pathway to overcome chemo resistance
#Onco404 #Cancer #Oncology #oncsky #medsky #ClinicalTrials #AACR #EGFR
📍 Key Highlights
✅ Targeted EGFR pathway to overcome chemo resistance
#Onco404 #Cancer #Oncology #oncsky #medsky #ClinicalTrials #AACR #EGFR
April 1, 2025 at 4:07 PM